Methods and compositions for inducing apoptosis of cells such as macrophages at a lesioned site of a body vessel are disclosed herein. Nitric oxide can be directly or indirectly delivered to a treatment site to increase macrophage apoptosis. Delivery can include site specific delivery of nitric oxide gas nitric oxide in aqueous solution or a substance(s) which releases nitric oxide or causes nitric oxide to be generated from an endogenous source. Delivery can be achieved by a delivery system suc...

Embodiments of the present invention include methods of treating preventing or ameliorating a vascular disease and/or disorder in a diabetic or pre-diabetic patient. The methods include implanting a stent in a vascular region in a diabetic patient and during the implantation procedure delivering a drug formulation from a source other than the stent to the vascular region. The stent may be a bare metal stent or a drug eluting stent such as a metal stent having a coating including a drug. The drug...

Methods of treating renal cancers and other kidney-related inflammatory disorders with a bioabsorbable polymer scaffold (such as a stent) are described. The treatments are provided as alternative to complete or partial surgical removal of a diseased kidney.

This invention is directed to methods of treating solid tumor cancers particularly refractory cancers by administration of a drug capable of inhibiting mTOR and/or inhibiting an efflux pump and/or inhibiting HIF-1alpha and VEGF the drug in particular being selected from the group consisting of sirolimus everolimus zotarolimus tacrolimus iolimus A9 deforolimus AP23572 tacrolimus temsirolimus pimecrolimus novolimus 40-O-(3-hydroxypropyl) 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin and 40-O-tetrazoly...

Methods and compositions for inducing apoptosis of cells such as macrophages at a lesioned site of a body vessel are disclosed herein. Nitric oxide can be directly or indirectly delivered to a treatment site to increase macrophage apoptosis. Delivery can include site specific delivery of nitric oxide gas nitric oxide in aqueous solution or a substance(s) which releases nitric oxide or causes nitric oxide to be generated from an endogenous source. Delivery can be achieved by a delivery system suc...

A drug-delivery system is provided including at least 100 ?g of everolimus and clobetasol such that the ratio of everolimus to clobetasol is at least 10:1 (w/w) or the amount of everolimus by weight is at least 10 times more than clobetasol. The system can be a stent. Also provided a method of treating restenosis or vulnerable plaque of a blood vessel the method includes locally administering to a patient a first drug selected from a group consisting of rapamycin (sirolimus) Biolimus A9 deforoli...

Methods and compositions for inducing apoptosis of cells such as macrophages at a lesioned site of a body vessel are disclosed herein. Nitric oxide can be directly or indirectly delivered to a treatment site to increase macrophage apoptosis. Delivery can include site specific delivery of nitric oxide gas nitric oxide in aqueous solution or a substance(s) which releases nitric oxide or causes nitric oxide to be generated from an endogenous source. Delivery can be achieved by a delivery system suc...

Drug-delivery systems such as drug-delivery stents having an anti-proliferative agent such as everolimus and an anti-flammatory agent such as clobetasol are provided. Also disclosed are methods of treating a vascular impairment such as restenosis or vulnerable plaque.